Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.34 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5732147 | 0.78 | SCN3A (0.30) | — | |
| SCHEMBL506865 | 0.76 | ESR1 (0.42) | NMT1HTTPARP15PARP10LMNA | |
| SCHEMBL5764333 | 0.74 | DRD2 (0.30) | — | |
| SCHEMBL10227504 | 0.72 | NMT1 (0.48) | NMT1HTTPARP15PARP10LMNA | |
| Hydrochloric Acid SCHEMBL507254 | 0.71 | NMT1 (0.48) | NMT1HTTPARP15PARP10LMNA | |
| SCHEMBL5787122 | 0.67 | HPD (0.39) | HTTLMNA | |
| SCHEMBL5763530 | 0.67 | CYP1A2 (0.34) | — | |
| SCHEMBL23315269 | 0.67 | AGTR2 (0.41) | PARP15PARP10NPC1RAB9ATDP1 | |
| SCHEMBL21881193 | 0.67 | AGTR2 (0.41) | PARP15PARP10NPC1RAB9ATDP1 | |
| SCHEMBL5732501 | 0.66 | DRD2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580780-B2 | 6 substituted 2, 3,4,5 tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonist | ELI LILLY AND COMPANY (US) | 2013-11-12 | — | — | US | disclosed |
| US-20120028961-A1 | 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist | ELI LILLY AND COMPANY (US) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028961-A1 | 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist | HTR2C, HTR4, HTR1A | NMT1 3747/4885HTT 581/4885PARP15 1574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.